Tagged with B

Saudi Arabia Khaled Harb, general manager of Saudi distributor Abdulrehman Algosaibi, highlights the changing distribution landscape in Saudi Arabia, the importance of offering comprehensive solutions that go beyond traditional services, what the updated role of procurement body NUPCO means for the industry, and shares his perspective on the Vision 2030 transformation.  …

Denmark Zealand Pharma’s Emmanuel Dulac, fresh from a first US FDA approval for the company’s rescue pen for severe hypoglycaemia in people with diabetes aged 6 years and older, outlines the swift progress that the Danish biotech has made in his two and a half years as CEO. Dulac also highlights…

Turkey Turkish Cargo, the global air cargo arm of Turkish Airlines, has the world’s largest direct cargo flight network excluding express carriers which has enabled them to deliver 320 million COVID-19 vaccine doses to more than 55 countries around the world. Turhan Özen, its chief cargo officer, explains their services for…

LatAm The latest from the healthcare industry in Latin America, including an alarming OECD report about the decline of well-being in the region due to Covid-19, Bayer’s USD 350 million investment in Costa Rica and Argentina combined, Mexico’s slow drug approval process, and Pfizer’s upcoming PR challenge.   Well-being weakened in…

Turkey Okan Güner of Viatris Turkey introduces the company’s sizeable footprint in the country, including local manufacturing and explains the challenges of executing an integration of two companies during the COVID-19 pandemic. Güner outlines Viatris’ role within Turkey’s Vision 2023, the opportunities for their biosimilars pipeline, and their portfolio’s role in…

Africa Three months after the World Bank announced a EUR 600 million loan to South Africa’s Aspen Pharmacare, the African continent has received more good news as it seeks to increase vaccine manufacturing know-how.   BioNTech, the company behind Pfizer’s mRNA-based COVID-19 vaccine, sold under the brand name Comirnaty, recently announced…

Italy Speaking recently to PharmaBoardoom, Assobiotec’s Leonardo Vingiani introduced the key dynamics shaping the Italian biotech industry today and the issues it still has to overcome to become truly globally competitive.   Strong Fundamentals The association’s latest reporting shows that there are 751 active biotech firms in Italy, with a turnover…

UAE Amgen MEA’s Mohamed Nasser* examines the current pharma commercialisation model, posits how the entire healthcare ecosystem’s rapid and effective response to COVID-19 could be replicable in other disease areas, and makes his predictions for the industry’s future direction.   Probably more than at any other time in history, the last…

Germany The latest news from German pharma, including Bayer’s USD 2 billion acquisition of San Diego’s Vividion Therapeutics; Boehringer Ingelheim’s new investment in a Vienna production facility; BioNTech’s plans to inaugurate an mRNA manufacturing network in Africa; and the termination of the GSK/Merck KGaA cancer drug partnership.   German drug giant…

Saudi Arabia In a recent royal decree, Saudi Arabia has appointed Fahad Al-Jalajel as its Minister of Health, replacing Dr Tawfiz Al-Rabia who had served since 2016. Here, we give a quick run-through of Al-Jalajel’s career thus far.   The holder of a bachelor’s degree in computer science from King Saud University,…

Saudi Arabia Recently appointed CEO of Saudi Chemical Company Holding’s Pharma Sector, Ismail Shehada is today drawing on 20+ years of Big Pharma experience to drive SCCH’s growing life sciences footprint in alignment with the Kingdom of Saudi Arabia’s Vision 2030 healthcare transformation. Shehada explains how SCCH is moving into third-party logistics…

Saudi Arabia Biogen’s manager for the Middle East, Africa, Russia & CIS, Turkey (MART), Ajai Sulekh, discusses the company’s five-pillar strategy to expand its footprint in the region, the importance of its newly established technical & scientific office in Saudi Arabia, and why the Kingdom is part of “almost every discussion” about…